Atlas Venture Life Science Advisors, LLC Q1 2023 Filing

Filed May 15, 2023

Portfolio Value

$738.6M

Holdings

16

Report Date

Q1 2023

Filing Type

13F-HR

All Holdings (16 positions)

#	Stock	Shares	Value	% Portfolio	Type
1	KYMRKymera Therapeutics, Inc.	5,858,262	$173.6M	23.50%
2	DYNDyne Therapeutics, Inc.	9,885,449	$113.9M	15.42%
3	DAWNDay One Biopharmaceuticals, Inc.	7,608,394	$101.7M	13.77%
4	IRONDisc Medicine, Inc.	3,461,784	$73.4M	9.93%
5	VIGLVigil Neuroscience, Inc.	5,836,874	$57.1M	7.74%
6	THRDThird Harmonic Bio, Inc.	10,907,859	$44.9M	6.08%
7	AVTEAerovate Therapeutics, Inc.	2,039,249	$41.1M	5.57%
8	REPLReplimune Group, Inc.	2,098,300	$37.1M	5.02%
9	GBIOGBXGeneration Bio, Co.	8,279,484	$35.6M	4.82%
10	AKROAkero Therapeutics, Inc.	594,251	$22.7M	3.08%
11	—Ikena Oncology, Inc.	5,018,178	$17.3M	2.34%
12	XLOXilio Therapeutics, Inc.	2,759,344	$8.7M	1.18%
13	—AvroBio, Inc.	4,541,381	$4.5M	0.61%
14	—Magenta Therapeutics, Inc.	3,791,698	$3.0M	0.41%
15	VRDNViridian Therapeutics, Inc.	90,072	$2.3M	0.31%
16	SPROSpero Therapeutics, Inc.	1,031,160	$1.5M	0.20%